Skip to content

Member

Romana JERKOVIĆ

S&D · Croatia

Group
S&D
Country
Croatia
Roll-call participation
84.0 %ⓘ of 620 roll calls in office · chamber median 90.6 % · whole term, final votes
With majority line
98.1 %ⓘ of 521 votes where the group had a line · S&D median 97.1 %
More facts (5)
National party
SDP Socijaldemokratska partija Hrvatske
In office
Since 16 Jul 2024
Against clear line
8 of 516 votesⓘ
Committees
EMPL (substitute), ENVI, SANT (vice-chair)
Member id
112747
More

Record

The member’s figures against the median of their group and of the chamber. Each vote counts the member in the group they belonged to that day.

Roll-call participation ⓘ

84.0 %

521 of 620 final votes while in office

S&D median: 89.5 % (−5.5 pts)

Chamber median: 90.6 %

With majority line ⓘ

98.1 %

511 of 521 votes where their group had a line

S&D median: 97.1 % (+1.0 pts)

Against clear line ⓘ

1.6 %

8 of 516 votes where their group had a clear line

1 opposite (for ↔ against), 7 abstained against the line

Abstention ⓘ

1.7 %

9 of 521 votes cast

Participation 84.0 % — S&D median 89.5 %, 137 members.ⓘ
Data as a table
Participation among the 137 members of the S&D with enough votes.
FigureParticipation
Romana JERKOVIĆ84.0 %
S&D median89.5 %
Lowest in the group48.1 %
Highest in the group99.8 %
Members137
With majority line 98.1 % — S&D median 97.1 %, 137 members.ⓘ
Data as a table
With majority line among the 137 members of the S&D with enough votes.
FigureWith majority line
Romana JERKOVIĆ98.1 %
S&D median97.1 %
Lowest in the group86.7 %
Highest in the group99.8 %
Members137
  • Whole term, 620 final votes; 620 of 794 decisions had a final vote recorded by name. The dots are the other members of S&D; no ranks.
  • “No vote recorded” is not the same as absent: leave, illness and chairing the sitting look the same.
  • A group’s line is inferred from its members’ votes — Parliament publishes no whip.

Votes, 5 928

Export

Every roll-call vote of the term with the member’s position, newest first.

Result: for–against–abstained. Majority line: how most of the member’s group voted that day (“Tie” when no position won). ≠ group marks a vote otherwise than a clear line (at least two thirds, with at least 10 members voting) of their group.
DateDecision and voteResultPositionMajority line
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Final vote — text as a wholeAdopted 434 for, 49 against, 168 abstainedPosition: For Majority line: For
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Amendment 12, adding text after paragraph 12 72 for, 522 against, 51 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement Final vote on the draft Council decisionConsent given 473 for, 114 against, 58 abstainedPosition: For Majority line: For
9 Sept 2025EU-Brazil Agreement: cooperation with and through Europol and the Federal Police of Brazil Final vote on the draft Council decisionConsent given 606 for, 5 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Final votePassed 431 for, 145 against, 76 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 395 to recital 19 187 for, 442 against, 16 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 409 + 417 (voted as one) to Annex VII, Part C, point 16 208 for, 431 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 371 to Annex VII, Part C, point 13 530 for, 112 against, 4 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 408 + 416 (voted as one) to Annex VII, Part C, point 6 204 for, 438 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 407 to Annex VII, Part C, point 4 137 for, 447 against, 61 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 318 to Article 55, après le paragraph 2 512 for, 120 against, 14 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 390 to Article 55, après le paragraph 2 105 for, 538 against, 3 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 389 to Article 38, paragraph 3, après le point b 96 for, 549 against, 3 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 388 to Article 18, paragraph 1 124 for, 515 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 387 to Article 7, après le paragraph 4 207 for, 431 against, 10 abstainedPosition: For ≠ groupMajority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 2 451 for, 182 against, 10 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 1 461 for, 185 against, 5 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 394 to Article 6, paragraph 1, après l'alinéa 2 142 for, 496 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 403 to Article 6, paragraph 1, alinéa 2 192 for, 442 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 130 to Article 6, paragraph 1, alinéa 1 444 for, 189 against, 14 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 402 to Article 6, paragraph 1, alinéa 1 194 for, 434 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 393 to Article 6, paragraph 1, alinéa 1 120 for, 529 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 2 438 for, 196 against, 8 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 1 452 for, 195 against, 2 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 134 to Article 6 473 for, 154 against, 22 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 2 512 for, 122 against, 15 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 1 505 for, 126 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 401 to Article 6 131 for, 447 against, 72 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 392 to Article 4, après le paragraph 1 138 for, 504 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 391 to Article 4, paragraph 1, après le point b 138 for, 508 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 399 + 412 (voted as one) to Article 3, paragraph 1, point 15 168 for, 445 against, 36 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 398 to Article 3, paragraph 1, après le point 9 199 for, 437 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 397 to Article 3, paragraph 1, point 9 158 for, 471 against, 17 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 396 to Article 2, paragraph 6, partie introductive 197 for, 418 against, 30 abstainedPosition: Against Majority line: Against
8 Sept 2025Wednesday’s agenda – Request by the PPE Group Ordre du jour de mercredi — Demande du groupe PPE 384 for, 10 against, 51 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Final vote — text as a wholeAdopted 523 for, 75 against, 14 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 1 to paragraph 14 157 for, 428 against, 36 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 8, adding text after paragraph 13 95 for, 420 against, 119 abstainedPosition: For ≠ groupMajority line: Abstained
10 Jul 2025Tackling China’s critical raw materials export restrictions Paragraph 13 — part 2 483 for, 84 against, 67 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 7 to paragraph 13 80 for, 407 against, 151 abstainedPosition: Abstained Majority line: Abstained
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 6, adding text after paragraph 12 79 for, 531 against, 18 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 5 to paragraph 10 47 for, 560 against, 27 abstainedPosition: For ≠ groupMajority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 4 to paragraph 8 88 for, 520 against, 22 abstainedPosition: For ≠ groupMajority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 3, adding text after paragraph 2 63 for, 552 against, 15 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 2, adding text after paragraph 1 123 for, 390 against, 110 abstainedPosition: Abstained Majority line: Abstained
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Final vote — text as a wholeAdopted 494 for, 83 against, 71 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 2, adding text after recital S 217 for, 409 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 1, adding text after citation 2 226 for, 409 against, 17 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 34 — part 2 566 for, 60 against, 23 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 32 — part 1 588 for, 56 against, 7 abstainedPosition: For Majority line: For

Show all 50 votes on this page

Roll-call participation

One cell per sitting while in office, shaded by the share of that day’s roll calls the member voted in. The official attendance register is kept separately by Parliament.

No vote recorded on 9 of 80 sittings with roll calls.

"No vote recorded" is not the same as absent: leave, illness and chairing the sitting look the same.

Data as a table

Voting neighbours

Members who voted the same way most often in the roll calls they both took part in, within and outside the member’s group (group at the date of each vote), over all roll calls of the term.

At least 200 shared roll calls over at least six months in office together. Within = both sat in the same group on the date of the vote; a member who changed group can appear on both lists. Baseline = the median agreement of all pairs of members of the groups the two sat in on the date of each shared vote (within: the group they shared; outside: the two groups), weighted by the votes they shared in each combination.

Within S&D

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in the same group (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of that group.
SelectMemberGroupCountryAgreementBaseline
Biljana BORZAN S&DCroatia97 % of 4 402 shared93 %
Marko VEŠLIGAJ S&DCroatia97 % of 3 491 shared93 %
Tonino PICULA S&DCroatia96 % of 4 616 shared93 %
Laura BALLARÍN CEREZA S&DSpain93 % of 3 552 shared93 %
Lina GÁLVEZ S&DSpain93 % of 3 728 shared93 %
José CEPEDA S&DSpain93 % of 3 901 shared93 %
Alicia HOMS GINEL S&DSpain93 % of 3 952 shared93 %
Sandro RUOTOLO S&DItaly93 % of 3 809 shared93 %
Katarina BARLEY S&DGermany92 % of 3 169 shared93 %
Irene TINAGLI S&DItaly92 % of 4 539 shared93 %

Show all 10 neighbours

Outside the group

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in different groups (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of the groups the two sat in on those votes (groups at the date, weighted by the votes shared in each combination).
SelectMemberGroupCountryAgreementBaseline
Jana TOOM RenewEstonia86 % of 3 935 shared86 %
Catarina VIEIRA GreensNetherlands85 % of 4 326 shared83 %
Kim VAN SPARRENTAK GreensNetherlands85 % of 4 289 shared83 %
Irena JOVEVA RenewSlovenia85 % of 4 360 shared86 %
Bas EICKHOUT Former memberGreensNetherlands85 % of 3 604 shared83 %
Vladimir PREBILIČ GreensSlovenia85 % of 3 963 shared83 %
Terry REINTKE GreensGermany85 % of 4 491 shared83 %
Ľubica KARVAŠOVÁ RenewSlovakia85 % of 3 377 shared86 %
Yvan VEROUGSTRAETE RenewBelgium85 % of 3 116 shared86 %
Jutta PAULUS GreensGermany85 % of 4 158 shared83 %

Show all 10 neighbours

Work

Seats in committees, delegations and intergroups, and the dossiers the member leads, shadows or negotiates.

Seats

Body: the committee, delegation or intergroup, with its kind. Role: the member’s role in it. From, To: the dates of the seat (“now” while it lasts).
BodyRoleFromTo
Committee on Employment and Social AffairsEMPL CommitteeSubstitute19 Jul 2024now
Committee on the Environment, Climate and Food SafetyENVI CommitteeMember20 Jan 2025now
Committee on Public HealthSANT CommitteeVice-chair29 Jan 2025now
Delegation to the Cariforum-EU Parliamentary CommitteeDCAR Joint parliamentary committeeSubstitute19 Sept 2024now
Delegation for relations with JapanD-JP DelegationMember19 Sept 2024now
Intergroup on Cancer and Rare DiseasesIG10-05 Intergroup / working groupMember27 Jan 2025now
Intergroup on DisabilityIG10-10 Intergroup / working groupMember11 Mar 2025now
Intergroup on Fighting against PovertyIG10-12 Intergroup / working groupMember24 Jan 2025now
Intergroup on the Future of Education and Skills for a Competitive EuropeIG10-14 Intergroup / working groupMember29 Jan 2025now
Intergroup on Mental HealthIG10-17 Intergroup / working groupMember5 Feb 2025now

Show all 17 seats

Dossiers

Dossier: the procedure the declaration names (“No dossier named” for a delegation without one). Role: rapporteur, shadow rapporteur, negotiator or delegation. Committee: the committee that appointed them. Date: of the declaration.
DossierRoleCommitteeDate
No dossier namedShadow rapporteurEMPL11 Jun 2026
An EU cardiovascular diseases strategyRapporteurSANT1 Apr 2026
Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organsShadow rapporteurSANT1 Apr 2026
The EU Youth Strategy 2019-2027Shadow rapporteur for an opinionSANT1 Apr 2026
No dossier namedCommittee vice-chairSANT28 Jan 2025
No dossier namedCommittee vice-chairSANT22 Jul 2024

Show all 6 dossier roles

Topics they work on (model-assigned)

Counts: dossiers they spoke on, led or amended, and their questions and motions.

In the chamber

Speeches and statements in plenary debates, newest first; the verbatim report is on Parliament’s site.

45 contributions recorded, 3 written statements; 3 on behalf of their group; 49 minutes of speaking time.

Show all 40 recent contributions

Questions and motions, 24

Parliamentary questions and motions for resolutions the member authored or co-signed, newest first.

Date: tabled. Title: the question or motion, with its id. Kind: written question or motion for a resolution, with the number of co-authors. Answer: the date of the answer to a question.
DateTitleKindAnswer
30 Jun 2026Follow-up to question for written answer E-001083/2025 on menstrual products: transparency and health risks E-10-2026-002698Written questionwith 43 co-authors18 Sept 2026
11 Feb 2026Burden of non-communicable diseases among vulnerable populations P-10-2026-000590Priority written question15 Apr 2026
9 Feb 2026MOTION FOR A RESOLUTION on World Cancer Day B-10-2026-0113Motion for a resolutionwith 7 co-authors—
3 Feb 2026Ensuring patient safety for all Europeans: the need to establish a warning system for disqualified medical professionals E-10-2026-000428Written questionwith 24 co-authors27 Mar 2026
28 Jan 2026Addressing the gender health gap in the new research and innovation programme (FP10) O-10-2026-000004Oral questionwith 35 co-authorsNot yet answered
15 Oct 2025Europe’s Beating Cancer Plan funding E-10-2025-004037Written question20 Jan 2026
18 Sept 2025Commission support for the Member States on ME/CFS research, data collection and medical education E-10-2025-003626Written question6 Nov 2025
17 Jul 2025Follow-up question (Written Question E-000942/2025) E-10-2025-002978Written questionwith 7 co-authors4 Sept 2025
27 Jun 2025Working conditions of doctors in Europe E-10-2025-002607Written questionwith 17 co-authors14 Aug 2025
27 Jun 2025New studies confirming carcinogenic effects of long-term exposure to glyphosate at relevant levels E-10-2025-002611Written questionwith 31 co-authorsNot yet answered

Show all 24 questions and motions

Amendments tabled in committee, 91

Committee amendment documents that carry amendments by the member, with how many are theirs.

Date: of the amendment document. Text amended: the dossier and the document’s id. Committee: where the amendments were tabled. Amendments: how many in the document are the member’s.
DateText amendedCommitteeAmendments
10 Sept 2026Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organs CJ64-AM-792138 CJ649
10 Sept 2026Amending Directives 2001/18/EC and 2010/53/EU as regards the placing on the market of genetically modified micro-organisms and the processing of organs CJ64-AM-792139 CJ6423
2 Sept 2026Guidelines for the employment policies of the Member States EMPL-AM-792013 EMPL35
15 Jul 2026General budget of the European Union for the financial year 2027 - all sections SANT-AM-789117 SANT18
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790936 CJ5344
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790953 CJ5339
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790938 CJ5313
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790937 CJ5336
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790935 CJ5331
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790005 CJ5326

Show all 91 amendment documents

Connections

Dossiers they lead or shadow, committees, party, delegation and other related pages.

Political group

National delegation

  • Delegation Croatia National delegation

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Data version
data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1 · methods
Retrieved
2 October 2026

Cite as

EU Parl Watch Research (2026). “Romana JERKOVIĆ”. Member record. memberId 112747. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/members/112747?page=77&scope=final&vscope=all (retrieved 2 October 2026). Official source: Member’s profile, European Parliament, https://www.europarl.europa.eu/meps/en/112747. Data: EP Open Data: member record, https://data.europarl.europa.eu/api/v2/meps/112747?format=application%2Fld%2Bjson (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1.
BibTeX
@misc{epw-member-112747,
  author = {{EU Parl Watch Research}},
  title = {{Romana JERKOVIĆ}},
  year = {2026},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/members/112747?page=77&scope=final&vscope=all}},
  url = {https://news.eu-parl.st-solutions.dev/members/112747?page=77&scope=final&vscope=all},
  urldate = {2026-10-02},
  publisher = {EU Parl Watch Research},
  note = {Member record. memberId 112747. Official source: https://www.europarl.europa.eu/meps/en/112747. Data: EP Open Data: member record (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1}
}